Physician profile
Suzanne P Handler
NPI 1851307797
$10,963.18
in general payments reported to CMS, 2019-2025
26 companies · $3,116 in 2025
The $3,116 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $561 · 2021: $508 · 2022: $1,953 · 2023: $1,934 · 2024: $2,428 · 2025: $3,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,468 · Education: $9.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,468.45 |
| Education | $9.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,984.60 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Abbvie INC. | $831.65 | 2022-2025 | |
| Horizon Therapeutics Plc | $788.45 | 2021-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $768.08 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $709.26 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $609.68 | 2020-2025 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $558.50 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $528.20 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Dompe US, INC. | $447.85 | 2022-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $406.24 | 2020-2025 | Acthar |
| Harrow Eye, LLC | $377.37 | 2024-2025 | Vevye |
| Allergan, INC. | $319.44 | 2019-2022 | |
| Rxsight INC | $296.32 | 2021-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Glaukos Corporation | $217.91 | 2020-2024 | Idose |
| Aerie Pharmaceuticals, INC. | $215.39 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $157.86 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $154.57 | 2019-2022 | |
| Biotissue Holdings INC. | $140.11 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.32 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $98.23 | 2021-2025 | |
| Kala Pharmaceuticals, INC. | $81.31 | 2019-2022 | |
| Thea Pharma INC. | $66.53 | 2023-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $31.64 | 2023 | Dextenza |
| Alexion Pharmaceuticals, INC. | $30.36 | 2019 | |
| Rayner Intraocular Lenses Limited | $23.20 | 2025 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
| Lumenis, INC | $20.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Handler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.